Skip to content
Open access · CC-BY via OpenAlex

mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging

Candice E. Van Skike, Ai‐Ling Lin, Raquel R Burbank, Jonathan J. Halloran, Stephen F. Hernandez, James Cuvillier, Vanessa Soto‐Cerrato, Stacy A. Hussong, Jordan B. Jahrling, Martin A. Javors, Matthew J. Hart, Kathleen E. Fischer, Steven N. Austad, Verónica Galván

Aging Cell · 2019 · ▲ 75 citations

Abstract

Cerebrovascular dysfunction and cognitive decline are highly prevalent in aging, but the mechanisms underlying these impairments are unclear. Cerebral blood flow decreases with aging and is one of the earliest events in the pathogenesis of Alzheimer's disease (AD). We have previously shown that the mechanistic/mammalian target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (mTOR) drives disease progression in mouse models of AD and in models of cognitive impairment associated with atherosclerosis, closely recapitulating vascular cognitive impairment. In the present studies, we sought to determine whether mTOR plays a role in cerebrovascular dysfunction and cognitive decline during normative aging in rats. Using behavioral tools and MRI-based functional imaging, together with biochemical and immunohistochemical approaches, we demonstrate that chronic mTOR attenuation with rapamycin ameliorates deficits in learning and memory, prevents neurovascular uncoupling, and restores cerebral perfusion in aged rats. Additionally, morphometric and biochemical analyses of hippocampus and cortex revealed that mTOR drives age-related declines in synaptic and vascular density during aging. These data indicate that in addition to mediating AD-like cognitive and cerebrovascular deficits in models of AD and atherosclerosis, mTOR drives cerebrovascular, neuronal, and cognitive deficits associated with normative aging. Thus, inhibitors of mTOR may have potential to treat age-related cerebrovascular dysfunction and cognitive decline. Since treatment of age-related cerebrovascular dysfunction in older adults is expected to prevent further deterioration of cerebral perfusion, recently identified as a biomarker for the very early (preclinical) stages of AD, mTOR attenuation may potentially block the initiation and progression of AD.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1111/acel.13057
Canonical
link ↗
Fetched
2026-06-13 MST

Cite this

APA
Skike, C.E.V., Lin, A., Burbank, R.R., Halloran, J.J., Hernandez, S.F., Cuvillier, J., Soto‐Cerrato, V., Hussong, S.A., Jahrling, J.B., Javors, M.A., Hart, M.J., Fischer, K.E., Austad, S.N., &amp; Galván, V. (2019). mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging. <em>Aging Cell</em>. https://doi.org/10.1111/acel.13057
Vancouver
Skike CEV, Lin A, Burbank RR, Halloran JJ, Hernandez SF, Cuvillier J, et al. mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging. Aging Cell. 2019. doi:10.1111/acel.13057.
BibTeX
@article{candice2019mTORdr, title = {mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging}, author = {Candice E. Van Skike and Ai‐Ling Lin and Raquel R Burbank and Jonathan J. Halloran and Stephen F. Hernandez and James Cuvillier and Vanessa Soto‐Cerrato and Stacy A. Hussong and Jordan B. Jahrling and Martin A. Javors and Matthew J. Hart and Kathleen E. Fischer and Steven N. Austad and Verónica Galván}, journal = {Aging Cell}, year = {2019}, doi = {10.1111/acel.13057}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings